• AJMCAJMC
  • Center for Biosimilars
Center for Biosimilars®
Center for Biosimilars®
Business Practice
View MoreBusinessDevelopmentLegalPolicyPracticeRegulatory
News
Media
All Videos
Insights
Interviews
Peer Exchange
Podcasts
Compendia
Bone Health
Dermatology
Diabetes
Gastroenterology
Hematology
Neurology
Oncology
Ophthalmology
Rare Disease
Respiratory
Rheumatology
Conferences
Conference Coverage
Conference Listing
CME/CE
Resources
Authors
Biosimilar Resources
Interactive Tools
Polls
WHEN CHOICE ARRIVES: Competition & Consequences
SubscribeBIOSIMILAR APPROVALS
  • About
  • Contact
  • Advisory Board
  • Do Not Sell My Information
  • Terms & Conditions
  • Privacy Policy

© 2023 MJH Life Sciences and Center for Biosimilars®. All rights reserved.

Advertisement
Business PracticeSee All >
  • Business
  • Development
  • Legal
  • Policy
  • Practice
  • Regulatory
  • About
  • Contact
  • Advisory Board
  • Do Not Sell My Information
  • Terms & Conditions
  • Privacy Policy
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.

ACCC Annual Conference

  1. home

Joseph Alvarnas, MD, Discusses Biosimilar Use at City of Hope

March 10th 2021

Video

Joseph Alvarnas, MD, a recent presenter at the Association of Community Cancer Centers annual meeting, discussed efforts to implement biosimilars at City of Hope, a clinical research center, hospital, and graduate medical school in Duarte, California.

Oncologists' Cost Sensitivity May Drive Biosimilar Uptake

March 9th 2021

Article

Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, discusses motivating factors that affect use of biosimilars in oncology.

Cardinal Health: Oncologists’ Comfort With Biosimilars Is on the Increase

March 8th 2021

Article

Survey results show that oncologists are embracing biosimilars not just in supportive care but for therapeutic uses also.

ACCC Virtual: Dr Wilfong of Texas Oncology Discusses Biosimilar Integration

March 5th 2021

Video

Lalan Wilfong, MD, an expert on value-based care, explains how Texas Oncology worked with physicians and payers to make biosimilars available for patients.

Advertisement
Advertisement